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Abstract
Background: Dupuytren’s contracture (DC) is a fibroproliferative disorder characterized by the progressive
development of a scar-like collagen-rich cord that affects the palmar fascia of the hand and leads to digital flexion
contractures. DC is most commonly treated by surgical resection of the diseased tissue, but has a high reported
recurrence rate ranging from 27% to 80%. We sought to determine if the transcriptomic profiles of fibroblasts derived
from DC-affected palmar fascia, adjacent phenotypically normal palmar fascia, and non-DC palmar fascial tissues
might provide mechanistic clues to understanding the puzzle of disease predisposition and recurrence in DC.
Methods: To achieve this, total RNA was obtained from fibroblasts derived from primary DC-affected palmar fascia,
patient-matched unaffected palmar fascia, and palmar fascia from non-DC patients undergoing carpal tunnel
release (6 patients in each group). These cells were grown on a type-1 collagen substrate (to better mimic their in
vivo environments). Microarray analyses were subsequently performed using Illumina BeadChip arrays to compare
the transcriptomic profiles of these three cell populations. Data were analyzed using Significance Analysis of
Microarrays (SAM v3.02), hierarchical clustering, concordance mapping and Venn diagram.
Results: We found that the transcriptomic profiles of DC-disease fibroblasts and fibroblasts from unaffected fascia
of DC patients exhibited a much greater overlap than fibroblasts derived from the palmar fascia of patients
undergoing carpal tunnel release. Quantitative real time RT-PCR confirmed the differential expression of select
genes validating the microarray data analyses. These data are consistent with the hypothesis that predisposition
and recurrence in DC may stem, at least in part, from intrinsic similarities in the basal gene expression of diseased
and phenotypically unaffected palmar fascia fibroblasts. These data also demonstrate that a collagen-rich
environment differentially alters gene expression in these cells. In addition, Ingenuity pathway analysis of the
specific biological pathways that differentiate DC-derived cells from carpal tunnel-derived cells has identified the
potential involvement of microRNAs in this fibroproliferative disorder.
Conclusions: These data show that the transcriptomic profiles of DC-disease fibroblasts and fibroblasts from
unaffected palmar fascia in DC patients are highly similar, and differ significantly from the transcriptomic profiles of
fibroblasts from the palmar fascia of patients undergoing carpal tunnel release.
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Dupuytren’s contracture (DC) is characterized by abnor-
mal thickening of palmar fascia into collagen-rich cords
that cause the fingers to bend and curl into a flexed and
contracted state [1]. Although this disease can occur in
both sexes, it is more common in men of Northern Eur-
opean descent [2-4] and typically presents in the 4th to
6th decade of life. DC has been reported to behave as a
heritable genetic disorder, with evidence that it arises
( i na tl e a s ts o m ec a s e s )f r o ma na u t o s o m a ld o m i n a n t
gene on chromosome 16 with variable penetrance [3].
Lifestyle factors including smoking or heavy drinking
[5,6], and heavy manual labor and hand trauma, have
also been linked to development of DC [7,8], as have
diabetes, epilepsy and hypercholesterolemia [9-11].
Treatment of DC remains problematic. A variety of
non-surgical interventions, including injection of steroids
[12] or gamma-interferon [13], use of creams based on
vitamin E [14], dimethyl sulphoxides [15], and ultrasound
therapy [16] etc. yield limited benefits. Recently, direct
injection of clostridial collagenase has been evaluated
with some promising results [17-19]. However, surgical
excision of the involved contracted tissue remains the
mainstay of therapy, supplemented with post-operative
splinting and physical therapy [20,21]. Alternative thera-
peutic approaches remain desirable since surgery carries
significant risks, including damage to the digital nerves
and blood vessels, damage to the underlying flexor ten-
dons, and wound healing failure with the possibility of
skin necrosis.
A particularly vexing feature of DC is its propensity for
recurrence despite the appearance of successful initial
treatment. Many patients eventually require multiple sur-
geries with a cumulative risk of morbidity. However, it
remains unclear what factors are responsible for recur-
rence of the disease. Apart from the possibility of a genetic
predisposition, it has been hypothesized that undetected
residual foci of incipient disease are present in the other-
wise normal appearing and uninvolved palmar fascia, and
that these cells represent sites of disease recurrence.
We have previously investigated the transcriptomic dif-
ferences between fibroblasts derived from diseased DC
cords versus fibroblasts from phenotypically normal pal-
mar fascia in patients undergoing carpal tunnel (CT)
release. These studies demonstrated intrinsic differences in
gene expression between these cell populations that per-
sisted even after propagation under cell culture. We have
now extended these studies to include fibroblasts from
macroscopically uninvolved (i.e. phenotypically normal)
palmar fascia surgically removed from patients with DC.
These fibroblasts, as well as fibroblasts from diseased DC
cords and control carpal tunnel fibroblasts, were cultivated
in cell culture on a type-1 collagen substrate to better
approximate the in vivo collagen-enriched environment
that these cells experience. The transcriptomic signatures
of these three cell types were then compared to answer the
question: do fibroblasts from phenotypically normal pal-
mar fascia in DC more closely resemble their counterparts
in phenotypically dissimilar DC cords, or cells from pheno-
typically similar carpal tunnel fascia?
Methods
Clinical specimens
Dupuytren’s contracture (DC) cord samples and small
samples of phenotypically normal palmar fascia tissue (PF)
w e r es u r g i c a l l ye x p l a n t e da tt h eH a n da n dU p p e rL i m b
Centre at St Joseph’s Health Care (SJHC), London, ON,
Canada. We also obtained phenotypically normal palmar
fascia from patients undergoing carpal tunnel release (CT)
in London, ON, Canada, and at the Allegheny General
Hospital, Pittsburgh, PA. The study protocol conformed
to the ethical guidelines of the 1975 Declaration of
Helsinki. All specimens were collected under Institutional
Review Board approval. Six patient samples of each tissue
type were used to derive fibroblasts for use in these
studies.
Primary cell culture
Primary cultures of fibroblasts were purified from the sur-
gically resected DC cord and matching specimens of nor-
mal appearing palmar fascia (PF), and from specimens of
normal palmar fascia of patients undergoing carpal tunnel
surgery (CT) as previously described [22,23]. The cultures
were maintained in a-MEM-medium supplemented with
10% fetal bovine serum (FBS, Invitrogen Corporation,
Carlsbad, CA) and 1% antibiotic-antimycotic solution
(Sigma-Aldrich, St Louis, MO). All cultures were har-
vested prior to the sixth passage, with no changes in cell
morphology observed during the in vitro expansion proto-
col. For the present study we used 6 primary DC and
patient-matched PF cell cultures as well as primary fibro-
blasts purified and expanded from 6 patients undergoing
surgical carpal tunnel release. Primary cultures of fibro-
blasts were grown on collagen monolayers as described
previously [24]. In brief, collagen was coated on 6-well tis-
sue culture plates with each well containing 880 μlo fr a t
tail (type-1) collagen and 200 μl of the neutralization solu-
tion (2 parts 0.34N NaOH and 3 parts 10x Waymouth
media) to a final concentration of 1.9 mg/ml. Following
collagen polymerization, primary cultures were grown in
a-MEM-medium containing 10% FBS and 1% antibiotic-
antimycotic solution and the cultures were left undis-
turbed at 37°C at 5% CO2 for 72 hours.
Total RNA extraction
Each well containing cells grown on collagen was treated
with 1 ml of 0.25 mg/ml of collagenase XI (Sigma-Aldrich)
at 37°C with gentle rotation for 20 mins, until the cells
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samples were collected and centrifuged for 4 minutes at
900 rpm to concentrate the cells into a pellet for RNA
purification. Total RNA was extracted using the RNeasy
Mini Kit (Qiagen Inc., Valencia, CA) according to the
manufacturer’s instructions. The concentration of the
extracted RNA was quantified using a Nanodrop ND-1000
Spectrophotometer (NanoDrop, Wilmington, DE) (absorp-
tion ratio 260/280 > 1.8). The samples were then analyzed
on an Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA) to ensure adequate sample quality and
absence of RNA degradation (RIN value > 8.0).
Microarray assays
Total RNA (1.5 μg/sample) purified from fibroblasts
derived from DC cord (n = 6), PF (n = 6) and CT (n = 6)
specimens was subjected to analysis with Human WG-6
v3.0 Expression BeadChips (Illumina, SanDiego, CA), each
of which contains six arrays on a single BeadChip. Each
array is comprised of >48,000 probes derived from human
genes in the NCBI RefSeq and UniGene databases. Each
array on the BeadChip thus provides genome-wide tran-
scriptional representation of well-characterized genes,
gene candidates, and splice variants. A total of 18 separate
samples were interrogated on the BeadChip arrays, i.e.,
there was no pooling of samples within groups. This
allowed us to evaluate sample to sample variability in gene
expression both within and across each group.
Total RNA was amplified using the Illumina
® Total-
Prep™RNA Amplification Kit (Ambion, Austin, TX).
Labeling and hybridization was performed according to
the Illumina gene expression protocol, featuring a reverse
transcription step to synthesize first strand cDNA followed
by addition of second strand master mix containing DNA
polymerase for second strand cDNA synthesis. This was
followed by a single in vitro transcription (IVT) amplifica-
tion step that incorporated biotin-labeled nucleotides.
Subsequent steps included array hybridization, washing,
blocking, and streptavidin-Cy3 staining followed by serial
non-stringent washing steps to remove unbound conju-
gate. Following the final rinse, the bioarrays were dried by
centrifugation and scanned. The Illumina bioarrays were
read in an Illumina BeadArray Reader and the primary
intensity data were obtained in standard file format, using
Genome Studio software.
Microarray expression analysis
The data obtained from the three cell sources were ana-
lyzed for differences in expression as previously described
using the multiclass analysis tool of the Significance Ana-
lysis of Microarrays program (SAM version 3.02) [23,25].
We then performed unsupervised hierarchical clustering,
concordance mapping and created Venn diagrams using
the Partek Genomics Suite version 6.4 (St. Louis, MO) to
evaluate similarities and differences in the gene expres-
sion patterns among the fibroblasts from each of the
three cell sources.
Pathway analysis
Statistically significant and differentially expressed genes
determined by SAM were subjected to systematic network
analysis to determine the primary biological processes and
pathways associated with each group using “Ingenuity
Pathways Analysis” (IPA, ver.5.0, Ingenuity
® Systems,
http://www.ingenuity.com, Mountain View, CA). Only
genes that were significantly increased or decreased were
included as a defined parameter for the core analysis.
Using information stored in the Ingenuity Pathways
Knowledge Base (IPKB), genes that mapped to genetic net-
works were ranked by a score based on the number of eli-
gible molecules contained in the network, which also
defines the probability that each network can be achieved
by chance alone. A score of 3 is considered threshold of
significance which means that there is a 1 in 1000 chance
that genes are integrated in the network by pure chance.
Canonical pathways were also identified from the IPA
library. The significance of the association between the
data set and the canonical pathway was measured in two
ways within the Ingenuity program: i) as a ratio of the
number of genes from the data set that map to the path-
way divided by the total number of genes that map to the
canonical pathway was calculated, and ii) by the Fischer’s
exact test which was used to calculate a p-value determin-
ing the probability that the association between dataset
genes and the canonical pathway is significant.
Quantitative real time RT-PCR
The protocol for reverse transcription reactions and real
time PCR was followed as previously described [23].
Ninety ng of total RNA and 150 ng of random primers
(Invitrogen Corporation) were used in 30 μLr e a c t i o n sa n d
real time RT-PCR was performed with triplicate sample
reads. The 18 samples were prepared separately such that
gene expression analysis was performed using individual
samples without pooling. Real time PCR amplification and
detection of template was carried out using Applied
Biosystems transcript-specific assays including: angiopoie-
tin-like 7 (ANGPTL7) - Hs00221727_m1, Laminin alpha
5(LAMA5) - Hs00966585_m1, Shroom 2 - Hs01113
636_m1, and GAPDH - Hs02758991_g1. Using the com-
parative critical cycle (Ct) method and using GAPDH as
the endogenous control, the expression levels of the target
genes were normalized using a 95% confidence interval.
The relative expression of the 18 samples (6 for each sub-
set) was averaged and statistical analysis for significance
was performed using a Student’s t-test. Results shown
are from two independent experiments performed in
triplicate.
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The raw intensity values representing expression of indi-
vidual transcripts were corrected by subtraction of the
background intensity for each array. All values that were
at or below background concomitantly in all 3 sample
groups were removed yielding 27214 transcripts for
further analysis. Box plot analysis of the distribution of
these intensity values across the three groups demon-
strated comparable dispersion of the individual data sets
regardless of patient source, eliminating the need for log
normalization or secondary smoothing of the raw inten-
sity data prior to statistical evaluation (Figure 1).
Transcript intensity values were analyzed for differ-
ences in individual gene expression levels using the mul-
ticlass comparison of the SAM program (Tusher et al.,
2001). The overall raw data distribution was not modified
prior to analysis except for median centering of the array
data within the SAM program. Results were considered
significant at a false detection rate (FDR) of 5% (q ≤ 0.05)
and the multiclass comparison revealed 959 transcripts
differentially expressed among the 3 classes (delta = 0.47
and FDR = 4.89%). Removal of cDNA clones, open read-
ing frame transcripts, redundant probes and transcripts
for hypothetical proteins among the 959 significant tran-
scripts revealed 724 distinct, functionally annotated gene
products that were differentially expressed among the 3
groups (Additional file 1).
Post hoc comparisons were performed on these 959 tran-
scripts against the Student’s t-distribution using the Partek
Software for paired (Dupuytren samples: DC and PF) and
the unpaired samples obtained during carpal tunnel release
(CT). Three separate univariate comparisons resulted in
894 transcripts detected as significantly different in DC vs
CT-derived fibroblasts, 816 significantly different tran-
scripts between PF and CT-derived fibroblasts, and 308 dif-
ferentially expressed transcripts between DC and PF-
derived fibroblasts. These lists are depicted in a Venn Dia-
gram (Figure 2) that illustrates the significant differences
specific to each set of individual comparisons (within a cir-
cle) versus those shared in more than one of the statistical
comparisons (shared between circles). For example, the
comparison of DC vs CT-derived fibroblasts yielded 21
transcripts in the non-overlapping area (blue) that were dif-
ferent between these cell types but were not significantly
different in the other two comparisons. In contrast, the
overlapping region between the PF versus DC circle (green)
and the DC vs CT circle (blue) contained 120 transcripts.
These 120 transcripts were significantly different in com-
parisons of DC to either PF or CT-derived fibroblasts but
were not different between PF and CT-derived fibroblasts
Figure 1 Box Plot Analysis of the Three Sample Groups. Box plot analysis of the distribution of the intensity values across the 3 groups
demonstrated comparable dispersion of the individual data sets regardless of cell source, eliminating the need for normalization or smoothing
of the raw data. 1-6: palmar fascia-derived fibroblasts (PF). 7-12: Dupuytren’s contracture-derived fibroblasts (DC). 13-18: carpal tunnel -derived
fibroblasts (CT)
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Venn Diagram that overlapped among all three circles,
indicating that these transcripts were significantly different
in all three comparisons. The most interesting observation,
however, is that 622 transcripts (pink) were significantly dif-
ferent in comparisons of CT- to both PF- and DC-derived
fibroblasts, but were similarly expressed in DC and PF cells.
Unsupervised hierarchical clustering was performed
using the Partek program on log base 2 intensity values
of the differentially expressed transcripts identified by the
SAM program. Agglomerative clustering was performed
to detect dissimilarity based on Euclidean distance with
clusters linked based on average values in order to deter-
mine if major variations existed in gene expression pro-
files among the 3 groups [26]. The program was set to
delineate the maximum number of clusters based on
individual sample comparisons. The primary branch of
the resulting dendrogram separated the transcripts of the
P Fa n dD C - d e r i v e df i b r o b l a s t sf r o mt h o s eo ft h eC T -
derived fibroblasts, indicating that significant differences
in expression were based on patient origin (Figure 3).
However, the DC- and PF-derived fibroblasts also formed
clearly distinct clusters separate from each other at the
next level of branching. Thus, all three cell groups exhib-
ited distinctly different expression signatures with the
greatest difference between the unpaired and the paired
(DC-derived) samples.
Concordance analysis was performed to delineate simi-
larities in expression profiles among samples. Concor-
dance was calculated using the initial dataset of 959
significant transcripts (log base 2) with similarity between
samples based on Euclidean distance (Figure 4). Relative
similarity is depicted by a color gradient where blue
represents the highest similarity diminishing to the most
different values represented in red color. The light blue
color at the blue-red interface was indicative of sample
identity. Based on this analysis, expression of PF- [1-6]
and DC-derived fibroblasts [7-12] exhibited the highest
similarity (blue) while both were markedly different from
CT-derived fibroblast [13-18] profiles, consistent with
the results obtained via hierarchical clustering.
Identification of biological pathways
Biological interactions among genes differentially expressed
between Dupuytren’s-derived and CT-derived fibroblasts
were identified using Ingenuity
® System Analysis. Two dis-
tinct gene sets of interest were analyzed: 1) genes concor-
dantly expressed between PF- and CT-derived fibroblasts
but significantly different in DC-fibroblasts (120 genes);
and 2) genes concordantly expressed between DC- and
Figure 2 Venn Diagram of Individual Group Comparisons Among the Three Sample Groups. Each of the circles depicts the number of
different transcripts based on a binary comparison for each of the labeled sample groups (green, orange, blue) from among the 959 transcripts
identified as statistically significant in the study (SAM). Overlapping differences shared among more than one sample group comparison are
represented in the areas of intersection between 2 circles. The 131 transcripts in the center of the Venn Diagram represents genes that are
different among all group comparisons. The number of transcripts in the carpal tunnel comparisons (622) far exceeded those in the palmar
fascia (55) and Dupuytren (120) comparisons
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Page 5 of 14Figure 3 Unsupervised Hierarchical Clustering of Expression Values Based on Sample Origin. The sample distributions of significantly
different transcripts (959 transcripts, SAM v. 3.02) are displayed based on unsupervised, hierarchical, agglomerative clustering (Partek: v. 6.4)o f
log base 2 intensity values. A primary branch of the dendrogram distinguishes the expression values obtained from transcripts of the palmar
fascia- and Dupuytren’s-derived fibroblasts from those of the carpal tunnel-derived fibroblasts, indicating a distinct difference based on these
tissues of origin. Dupuytren’s and palmar fascia-derived fibroblasts also formed distinct clusters separate from each other at the next branching
level despite their matched patient origin
Figure 4 Concordance Analysis of Individual Sample Profiles of Gene Expression. Concordance was calculated (Partek) using the initial
dataset of 959 significant transcripts (log base 2) with similarity between samples derived through Euclidean distance based on Euclidian distance.
Relative similarity among samples based on labeled origin is depicted through a color gradient where dark blue represents highest similarity of
expression values on the scale diminishing across a gradient to the most different values represented in dark red color. The light blue color at the
blue-red interface is indicative of sample identity. Based on this analysis, palmar fascia- [1-6] versus Dupuytren-derived fibroblast samples [7-12]
exhibited highest similarity (blue), while both were substantially different from carpal tunnel-derived fibroblast [13-18] expression profiles
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The program identified 19 and 172 genes respectively that
were eligible for function/pathway analysis, comprising 2
and 12 networks respectively with scores of 3 or greater
(Tables 1 and 2). The 19 eligible genes identified from the
first gene set represented functional categories such as cell
death, cell cycle, cellular growth and proliferation- all
understandably relevant to a fibroproliferative process like
Dupuytren’s( T a b l e1 ) .
In contrast, the 172 genes and 12 networks identified
from the second gene set included a much broader array
of functional categories, ranging from DNA replication,
recombination and repair, to cellular development and cell
morphology, to cell-to-cell signaling and interaction. The
genes identified were also implicated in a host of other
functions including drug metabolism, endocrine system
development and function, tumor morphology, molecular
transport and even lipid metabolism (Table 2). What role
each of these may play in the progression or recurrence of
Dupuytren’s pathology is as yet unclear.
An interesting feature of the Ingenuity analysis is that the
data suggest the involvement of microRNAs (miRNAs) in
the dysregulated processes leading to DC pathology. In
examining the 120 genes concordantly expressed between
PF- and CT-derived fibroblasts but significantly different in
DC-fibroblasts, Ingenuity analysis identified two networks
which showed direct interaction of three miRNAs, namely
miRNA106A, miRNA17 and miRNA20B (Table 1). Micro-
RNA involvement is also suggested by analysis of the genes
concordantly expressed between DC- and PF-fibroblasts
but significantly different in CT. Three microRNAs are
putatively implicated: miRNA202, miRNA122, miRNA214
(Table 2).
Validation of the differential expression of select gene
products by quantitative RT-PCR
Quantitative real time RT-PCR was performed on the
same RNA extracted for the microarray analysis on
select genes to validate the microarray results (shown in
Figure 5). The genes selected for such confirmation
have not previously been reported to be differentially
expressed in CT-, PF- or DC-derived fibroblasts. Angio-
poietin-like7 mRNA (ANGPTL7) was significantly
decreased in DC-derived fibroblasts compared to both PF-
and CT- derived cells, amongst which no significant differ-
ence was seen (Figure 6a). LAMA5 mRNA was similarly
least in DC-derived cells, but was also significantly less in
PF- compared to DC-derived cells (Figure 6b). In contrast,
Shroom2 message was dramatically increased in DC-
derived fibroblasts compared to both CT- and PF-derived
fibroblasts (Figure 6c). As can be seen by comparing the
gene expression patterns in Figures 5 and 6, in each case
quantitative RT-PCR findings closely matched the results
from microarray analysis.
Discussion
We previously reported significant differences in gene
expression that distinguish fibroblasts obtained from
Dupuytren’s Contracture cords versus fibroblasts obtained
from the normal fascia of patients undergoing surgical
therapy for carpal tunnel syndrome [23]. The culture con-
ditions in this study were modified from our previous
report through the use of a type-1 collagen substrate as
opposed to an uncoated standard plastic surface. Although
the morphological phenotype of the fibroblasts appeared
unaffected, many more differentially expressed genes (894
total) were detected in DC versus CT fibroblasts compared
to the previous study (40 differentially expressed genes by
Illumina BeadArray). Our results can be interpreted to
indicate that palmar fascia fibroblasts are sensitive to their
culture substrate at a molecular level despite minimal
changes in morphological appearance and behavior. These
findings can also be interpreted in light of our previous
studies indicating that total cellular ß catenin levels in DC
cells are altered by interactions with a type-1 collagen sub-
strate [24]. Consistent with this, Ingenuity analysis on
Table 1 Ingenuity analysis of genes concordantly expressed between PF- and CT-derived fibroblasts but significantly
different in DC-fibroblasts
ID Molecules in Network Score Focus
Molecules
Top Functions Canonical Pathways
1 ARID4B, ATRX, C1ORF25, CCL7, CDKN1A, CEP350,
EGLN1, EPOR, FAM124B, FBXO9, GRIN1, HDAC1,
HNF1A, IMPA2, KCNE4, MIR106A (includes
EG:406899), MIR17 (includes EG:406952), MIR20B
(includes EG:574032), MXI1, MYC, MYCT1, NFIA,
NFkB (complex), NRG1, PPARA, RORA, SAP130,
SEMA4B, Sin3A, SKP1, SUDS3, TNF, TRIP6, ZNF442,
ZNF33B
53 18 Cell Death, Cell
Cycle, Cellular
Growth and
Proliferation
DNA Methylation and Transcriptional Repression
Signaling, Toll-like Receptor Signaling, TREM1
Signaling. Erythropoietin Signaling, PXR/RXR
Activation, LXR/RXR activation, Melatonin Signaling,
Chemokine Signaling, PPAR Signaling, FXR/RXR
Activation, HIF1∝ Signaling, Hepatic Cholestasis, Aryl
Hydrocarbon Receptor Signaling, Inositol Phosphate
Metabolism, PPAR∝/RXR∝ Activation, Production of
Nitric oxide and Reactive Oxygen Species in
Macrophages, LPS/IL-1 Mediated Inhibition of RXR
Function, Axonal Guidance Signaling
2 HSPB3, LSM14B 3 1 Cellular
Compromise,
Cellular Function
and Maintenance
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in CT
ID Molecules Score Focus
Molecules
Top Functions Canonical Pathways
1 ABCG5, Ap1, BIRC3, CASP1, Caspase, CCR6,
Creb, CSF2RA (includes EG:1438), DAPP1,
DDOST, DMC1, ERK1/2, HNRNPU, IL1, IL18,
IL12 (complex), IL17RD, Jnk, LEP, MECOM,
NAPB, NFkB (complex), PDGF BB, PNPT1,
RAD51, RNF31, SLC12A4, SSTR2, STAT5a/b,
SUMO1, TNFSF14, TNFSF15, TP53BP2,
UNC5B, XRCC2
47 25 Cell Cycle, DNA Replication,
Recombination, and Repair,
Metabolic Disease
Pyrimidine Metabolism, Artherosclerosis
Signaling, TREM1 Signaling,
Glycosphingolipid Biosynthesis-Lactoseries,
Death Receptor Signaling, Nucleotide
Sugars Metabolism, Aminosugars
Metabolism, LXR/RXR Activation, Axonal
Guidance Signaling, FXR/RXR Activation,
Amyotrophic Lateral Sclerosis Signaling,
Endothelin-1 Signaling, N-Glycan
Degradation, Cholecystokinin/Gastrin-
mediated Signaling, p38 MAPK Signaling,
Glycosaminoglycan Degradation, T Helper
Cell Differentiation, Graft-versus-Host
Disease Signaling, Ovarian Cancer Signaling,
Chondroitin Sulfate Biosynthesis, Role of
Cytokines in Mediating Communication
between Immune Cells, Lymphotoxin b
Receptor Signaling, Role of BRCA1 in DNA
Damage Response, Dendritic Cell
Maturation, Induction of Apoptosis by HIV1,
IL-10 Signaling, JAK/STAT Signaling, GM-CSF
Signaling, Hypoxia Signaling in the
Cardiovascular System, Communication
between Innate and Adaptive Immune
Cells, Antiproliferative Role of Somatostatin
Receptor 2, Linoleic Acid Metabolism, Acute
Phase Response Signaling, Acute Myeloid
Leukemia Signaling, leptin Signaling in
Obesity, Altered T Cell and B Cell Signaling
in Rheumatoid Arthritis, Role of Pattern
Recognition Receptors in Recognition of
Bacteria and Viruses, PPAR Signaling,
Apoptosis Signaling, IL-6 Signaling, Crosstalk
between Dendritic Cells and Natural Killer
Cells, p53 Signaling, Chronic Myeloid
Leukemia Signaling,
2 ACTR3, ACVR2A, ADCY, AHR, Akt, CAPZA1,
CHRNA5, Ck2, CTDP1, ERK, FLNC, FSH,
ganglioside GD1b, GATA6, hCG, Histone h3,
Histone h4, HSD17B7, Lh, MAGT1, Mapk,
MIR124, NELF, NME2, P38 MAPK, PI3K, Pka,
PPIB, PROS1, RNA polymerase II, SNAPC4,
STAR, STMN1, UPP1, USP49
33 19 DNA Replication,
Recombination, and Repair,
Drug Metabolism, Endocrine
System Development and
Function
Pyrimidine Metabolism, Purine Metabolism,
N-Glycan Biosynthesis, Axonal Guidance
Signaling, Androgen and Estrogen
Metabolism, Factors Promoting
Cardiogenesis in Vertebrates, Coagulation
System, RhoA Signaling, Role of NANOG in
Mammalian Embryonic Stem Cell
Pluripotency, AMPK Signaling, Estrogen-
Dependent Breast Signaling, Activation of
IRF by Cytosolic Pattern Recognition
Receptors, Wnt/b-catenin Signaling,
Caveolar-mediated Endocytosis Signaling,
Ephrin Recpetor Signaling, NRF2-mediated
Oxidative Stress Response, TGF-b Signaling,
Protein Ubiquitination Pathway, Thrombin
Signaling, Regulation of Actin-based Motility
by Rho, Virus Entry via Endocytic Pathways,
Fcy Receptor-mediated Phagocytosis in
Macrophages and Monocytes
3 C10ORF58, C6ORF170, CCNB2, CDC7, CPSF4,
FBXL12, FCAR, FKBP11, GADD45B, IL9, IL24,
Il12 receptor, ITIH3, ITIH5, ITPA, KIAA0101,
MAN2B2 (includes EG:23324), MARK3,
MCART1, NFYB, PCNA, PFN2, PGRMC1,
PILRA, POLD1, PTGS1, RORA, RRAD, STAT4,
TBX21, TERT, TGFB1, TGFBR2, XBP1, ZNF394
22 14 Cellular Development, Cell
Morphology, Cell-Mediated
Immune Response
Pyrimidine Metabolism, Purine Metabolism,
Cleavage and Polyadenylation of Pre-mRNA,
Eicosanoid Signaling, Endothelin-1
Signaling, N-Glycan Degradation,
Arachidonic Acid Metabolism, Ovarian
Cancer Signaling,
Satish et al. BMC Medical Genomics 2012, 5:15
http://www.biomedcentral.com/1755-8794/5/15
Page 8 of 14Table 2 Ingenuity analysis of genes concordantly expressed between DC- and PF-fibroblasts but significantly different
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4 Amino acids, BACE1, BLZF1, C1D, CBR3,
CCAR1, CDC6, COL4A3BP, CSNK1G2, EXO1,
FEN1, GSTA5, HNF4A, MCM4, MCM5, MCM6,
MCM8, MEG3 (includes EG:55384), MLH1,
MST1, PMM1, PPARG, PPP1R15B, PRKY,
PTGR2, RAB2A, RORC, SAP30BP, SFRS11,
SORBS1, STK16, TEAD3, TP53, VDAC2,
XPNPEP3
21 14 Tumor Morphology, Cancer, Cell
Cycle
Wnt/b-catenin Signaling, Inositol
Metabolism,
5 C12ORF24, C3ORF34, C4ORF43, CBR3,
CDKN2AIPNL, CEBPB, CYP1A1, D-glucose,
DAG1, DCAF13, ETFDH, F7, FKTN, HNF1A,
HNF4A, IL1B, INS, LRSAM1, MAPK8, NCK1,
NFkB (complex), PHF23, POFUT1, PRR3,
SESN2, SLC25A32, SP1, SRC, TSG101,
UBE2D3 (includes EG:7323), UBE2N, ZNF557,
ZNF577
20 13 Carbohydrate Metabolism,
Molecular Transport, Small
Molecule Biochemistry
6 ATP, BACE1, C14ORF153, CASP3, CRCP,
CTSD, EEF2, EIF2AK3, ERBB2, EREG, ERP29,
FUT3, GALNT3, ganglioside GD1a, GHR,
GRIPAP1, HIVEP2, HLA-DRA, HRAS, IL24,
MSH2, MYO9B, N4BP2, NLRP3, ODZ3,
PPP1R15A (includes EG:23645), PRTN3, RFX4,
RFXANK, Rsk, SERPINE2, Shc, Sod, SULT1A1,
TNF
19 13 Cellular Assembly and
Organization, Tissue
Morphology, Cell Death
Pyrimidine Metabolism, Purine Metabolism,
Cysteine Metabolism, Glycosphingolipid
Biosynthesis-Lactoseries, Sulfur Metabolism,
Glycosphingolipid Biosynthesis-
Neolactoseries, O-Glycan Biosynthesis,
Keratan Sulfate Biosynthesis, Chondroitin
Sulfate Biosynthesis, BMP Signaling
Pathway, NRF2-mediated Oxidative Stress
Response, EIF2 Signaling
7 C9ORF80, CDC45L, CTSD, DEFB1, EEF2,
Eotaxin, ERAP2, GADD45B, GHR, GRM8,
HMGA1, IFNB1, IFNG, IRF9, LILRB3 (includes
EG:11025), LIMK1, LMNB2, MSH2, MSH3,
MYC, ORC1L, ORC2L, ORC6L, PHC2, PNPT1,
RHOB, Rock, ROCK2, RPL7, SEPHS2,
SERPING1, STK11, TLE1, TMEM70, UTY
18 12 Cell Cycle, Gene Expression,
Inflammatory Response
Pyrimidine Metabolism, Nucleotide Sugars
Metabolism, Aminosugars Metabolism,
Axonal Guidance Signaling,
Cholecystokinin/gastrin-mediated Signaling,
Complement System, RhoA Signaling,
Glycosaminoglycan Degradation, CCR3
Signaling in Eosinophils, Selenoamino Acid
Metabolism, Semaphorin Signaling in
Neurons, Acute Phase Response Signaling,
Ephrin Receptor Signaling, Chemokine
Signaling, Leukocyte Extravasation Signaling,
VEGF Signaling, Thrombin Signaling
8 AIRE, C15ORF63, Ca2+, CTSD, D-glucose,
DAPK3, EEF2, ganglioside GM3, GBA2, GH1,
GHR, GLYCOGEN PHOSPHORYLASE, GPR1,
GRB2, heparin, HTT, LTF, MCHR2, MYL2,
MYO3B, NISCH, P2RX7, PFN2, PKC ALPHA/
BETA, PLA2G12A, PLA2G2D, Pld, PPA2,
PPP1R12A, PPP1R1A, PPP3CA, PRF1, SELL,
SLC7A9, SORBS1
16 11 Cell Signaling, Molecular
Transport, Vitamin and Mineral
Metabolism
Primary Immunodeficiency Signaling, Starch
and Sucrose Metabolism, Atherosclerosis
Signaling, Oxidative Phosphorylation,
Eicosanoid Signaling, Cyanoamino Acid
Metabolism, Stillbene, Coumanine and
Lignin Biosynthesis, Phospholipid
Degradation, Endothelin-1 Signaling, p38
MAPK signaling, MIF Regulation of Innate
Immunity, CCR3 Signaling in Eosinophils,
Arachidonic Acid Metabolism,
Glycerophospholipid Metabolism, Linoleic
Acid Metabolism
9 ARRB2, beta-estradiol, CCL5, CCL13, CCR5,
Creatine Kinase, CSNK1A1L, EEF2, EIF2AK2,
FOXO1, GAR1, HSP90AB1, KPNB1, KRI1,
LAGE3, NHP2, OSGEP, OTUD5, PCNA,
PPM1K, RAF1, RAN, RANGRF, RPLP0
(includes EG:6175), RPS6, SNRPE, SPN, SPRY2,
SPRYD5, TACR1, TGFBR2, TNFRSF1B, TRAF3,
XPO1, XPO5
16 11 Cell Death, Cell-mediated
Immune Response, Cellular
Movement
Leukocyte Extravasation Signaling
10 ALPHA AMYLASE, AMY1A, AMY1B, BMP8B,
CD44, CSF1, DAG1, DNAH6, DYNLT1, EPO,
FOXO1, FOXO3, FYN, glycogen, GRIN1,
HCLS1, IL15, INPPL1, KCNH6, LCK, LMOD3,
MIR9-1 (includes EG:407046), NMT1, oleic
acid, PLCG2, Pld, PLIN5, RPS4Y2, Shc, SHC1,
SHCBP1, TDRD1, VCAM1, VEGF
15 11 Cellular Development, Cell
Cycle, Cell Death
Starch and Sucrose Metabolism, Factor
Promoting Cardiogenesis in Vertebrates,
Role of NANOG in Mammalian Embryonic
Stem Cell Pluripotency, Role of Osteoblasts,
Osteoclasts and Chondrocytes in
Rheumatoid Arthritis, Basal Cell Carcinoma
Signaling, BMP Signaling
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11 ASB1, BEGAIN, C1ORF9, C8ORF45, CCDC85B,
CTSD, DEFB103A, Eotaxin, EREG, ganglioside
GD1a, ganglioside GD1b, ganglioside GM1,
ganglioside GM2, ganglioside GM3,
ganglioside GT1, GHR, IL32, KIAA0408, LHX4,
MAFF, MAPK1, MIR202 (includes EG:387198),
NDUFA5, NEUROG3, NRP1, PCBP2, PDE4C,
PSAP, ROBO1, SEMA3D, SEMA3E, Sphk, TNF,
ZFP36, ZNF337
14 12 Lipid Metabolism, Small
Molecule Biochemistry, Cell
Morphology
Purine Metabolism, Aminosugars
Metabolism, Oxidative Phosphorylation,
Lipid Antigen Presentation by CD1, Axonal
Guidance Signaling, Ubiquinone
Biosynthesis
12 ACTN1, BCAS2, C16ORF72, COPS2, CTTNBP2,
CTTNBP2NL, DNTTIP2, EGR1, ESR1, ESR2,
FAM40A, FAM40B, FAM63B, G alphai, JUN,
MCC, MCM2, MIR122, MIR214 (includes
EG:406996), MOBKL3, NR0B1, NR2F1, NRIP1,
PPP2R1A, PTEN, retinoic acid, RNF122, RP6-
213H19.1, SIKE1, STK24, STK25, STRN, STRN3,
TRAF3IP3
9 7 Gene Expression, Cellular
Development, Cellular Growth
and Proliferation
Oxidative Phosphorylation
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Figure 5 Expression of ANGPTL7, LAMA5 and SHROOM2 as Determined by Microarray Analysis. Differential expression of (a) ANGPTL7, (b)
LAMA5 and (c) SHROOM 2 between CT-, PF- and DC-derived fibroblasts in the microarray. Signal intensities (in arbitrary units, after subtraction of
background) for each gene product are shown. Statistical significance was derived using Significance Analysis of Microarrays program (SAM
version 3.02). p < 0.05 was considered significant
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Page 10 of 14genes concordantly expressed between DC- and PF- but
significantly different in CT-derived cells suggests the
involvement of molecules in the Wnt/b-catenin signaling
pathway. The gene encoding ß catenin, CTNNB1, was not
amongst the dysregulated genes identified in this analysis,
consistent with the primary regulation of cellular ß catenin
levels through post-translational mechanisms rather than
transcriptional induction [27]. Viewed in combination, our
findings suggest that the sensitivity of fibroblasts derived
from the palmar fascia of DC patients to their immediate
environment is evident at both transcriptomic and proteo-
mic levels. These findings may have profound implications
for in vitro culture models designed to replicate DC in
vivo and highlight the potentially important effects of cul-
ture substrates on cellular phenotypes.
There are at least two non-exclusive, potential explana-
tions for the marked differences in gene expression
between primary palmar fascia fibroblasts grown on plastic
tissue culture trays and those grown on a type-1 collagen
substrate. The collagen concentration used for these
analyses was 1.9 mg/ml, yielding a relatively soft substrate
that can be readily contracted by differentiated myofibro-
blasts in fibroblast populated collagen lattice assays [24].
A stiff and non-deformable substrate, such as tissue cul-
ture plastic, may promote myofibroblast differentiation in
a similar manner to that induced by increased tissue den-
sity [28]. This differentiation may be due, at least in part,
to the activation of latent TGF-ß1 secreted by these cells
into their extra-cellular matrix [29]. Under these culture
conditions, the differences in gene expression in primary
fibroblasts from different tissues may be masked by the
changes in gene expression induced during myofibroblast
differentiation. In contrast, a soft and readily deformable
type-1 collagen substrate may have prevented substrate
induced myofibroblast differentiation and allowed for
more sensitive detection of the original changes in gene
expression that more closely reflect the tissues of origin.
Additionally, collagens have been reported to induce a
“proliferation permissive” signal through a beta1 integrin-
mediated PI3 Kinase/Akt pathway in fibroblasts in other
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Figure 6 Real time RT-PCR Quantitation of ANGPTL7, LAMA5 and SHROOM2 in CT-, PF-, and DC-derived cells. Differential expression of
(a) ANGPTL7, (b) LAMA5 and (c) SHROOM2 was directly confirmed by qRT-PCR in CT-, PF- and DC-derived fibroblasts. Values are mean ± SEM of
two independent experiments performed in triplicate. GAPDH was used as an internal control. Statistical analyses were performed by Student’s t
test. Relative quantification of gene expression was calculated by comparing δ Ct values between CT-, PF- and DC- derived fibroblasts. p < 0.05
was considered significant
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Page 11 of 14systems [30]. Interactions with type-1 collagen may, there-
fore, activate gene transcription through this, and possibly
other, pathways in CT, PF and DC cells and induce the
differential expression of genes that are not activated in
the absence of collagen. Thus, culturing primary fibro-
blasts on a type-1 collagen substrate could induce any or
all of these effects and explain the marked increase in dif-
ferentially expressed genes identified in our analyses.
It is notable that each different cell group (DC vs. PF vs.
CT) displays a remarkable internal consistency. Six unre-
lated individuals are compared in each cell group and
were found to have highly similar transcriptomic profiles,
as evidenced by both hierarchical clustering and concor-
dance mapping. This lends confidence to interpretation of
our data as a meaningful representation of the actual dif-
ferences between the tissue and disease states examined.
The most compelling observation is that palmar fascia
fibroblasts from phenotypically normal tissue in DC
patients closely resemble (but, importantly, are not tran-
scriptomically identical to) cells derived from clearly
phenotypically abnormal tissue. As a corollary, both fibro-
blasts from diseased DC cords and uninvolved DC fascia
are markedly transcriptomically dissimilar to fibroblasts
from carpal tunnel fascia. This observation is strongly sug-
gestive that a major contributor to the tendency for DC
recurrence may be a genetic predisposition towards dis-
ease of phenotypically normal palmar fascia in DC
patients. Such an interpretation would be consistent with
previous reports that DC has a genetic basis {eg. Hu et al.,
2005 [3]}. Our findings may also reflect on recent reports
suggesting that DC cells may be derived from mesenchy-
mal stem cells (MSCs) in perinodular fat and skin [31].
While our analyses do not rule out the possibility that
MSCs from these tissues contribute to (or perhaps initiate)
disease progression or recurrence, the marked similarity
between the transcriptomes of DC and PF cells and their
relative dissimilarity to CT cells strongly implies that the
vast majority of cells in DC cord tissue are likely to be
derived from PF cells.
These observations make it possible to consider the
progression and recurrence of DC in a model based on
principles first elucidated in tumor biology, the so-called
“two-hit hypothesis” [32] first described by Nordling in
1953 [33]. In such a model we hypothesize that an inher-
ited allelic defect (or possibly a group of allelic defects)
constituting a first “hit” alters palmar fascial physiology
i nD Cp a t i e n t s ,b u tn o ts u f f i c i e n t l ys oa st ol e a dt ot h e
DC nodule/cord phenotype. Progression to frank and
active disease would require a second somatic mutation
(the second “hit”) in the remaining allele in the affected
tissue type. Such a model would account for the observa-
tion that DC is a heritable disorder, usually presenting
later in life (with correspondingly greater chances of hav-
ing accrued the second requisite mutation), but with
widely varying penetrance. Given that both PF and DC
cells display hundreds of genes differentially expressed at
the mRNA level compared to control CT cells, the puta-
tive etiological locus may be involved in transcriptional
regulation. Of course, it remains possible that DC is a
heterogeneous disorder with a similar phenotype arising
from multiple disparate underlying genetic loci, nor does
such a model eliminate the possibility of de novo sporadic
cases of DC.
These findings also have potential implications for in
vitro studies designed to dissect the molecular mechan-
isms of DC. If patients with a genetic predisposition to
develop DC have inherited PF cells that exhibit profound
differences in gene expression to normal palmar fascia
(CT) cells, then PF cells represent the most clinically
relevant controls for testing treatments designed to pre-
vent DC progression. In contrast, normal palmar fascia
cells, such as CT cells, are valuable for analyses designed
to identify the molecular characteristics that distinguish
DC cells from normal cells. Thus, while identifying differ-
ences in signaling pathway activation between DC and
CT cells [34] are useful analyses to characterize differ-
ences from normality, it is clearly essential that such
pathways are also assessed in PF cells before they are
considered potential therapeutic targets. A study by Pave-
lic et al., [35] employing a proteomic approach has iden-
tified several proteins interacting in various signaling
pathways in DC tissues when compared to unaffected
palmar fascia from DC patients. This identification of
protein-protein interaction potentially opens new thera-
peutic targets to reduce the recurrence of DC. Optimally,
comparisons of DC cells to both CT and PF cells are
likely to provide different, but equally valuable, insights
into DC progression and recurrence that will allow
researchers to distinguish and identify molecular or other
therapies that target DC, but not PF or CT, cells.
The remarkable internal consistency between samples
in the microarray was also reflected in the findings
obtained from real time RT-PCR assays used to validate
the microarray results. In seeking potentially novel tar-
gets to limit the progression of DC, we chose to directly
examine three select genes that have not been previously
implicated in the progression or recurrence of DC.
Human ANGPTL7 had been characterized as a potent
target gene of the WNT/b-catenin signaling pathway
and currently is a pharmacogenomics target in the fields
of oncology and regenerative medicine [36]. Studies by
K u c h t e ye ta l . ,( 2 0 0 8 )[ 3 7 ]a n ds u b s e q u e n ts t u d i e sb y
Comes et al., (2010) [38] showed that ANGPTL7 has
the potential to alter extracellular matrix formation, a
finding that may also be relevant to DC. We find that in
DC-derived fibroblasts ANGPTL7 mRNA is substantially
decreased in comparison to CT- and PF-derived fibro-
b l a s t s( F i g u r e5 aa n d6 a ) .T h ef u n c t i o n a li m p o r t a n c eo f
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studies are required to understand its role in DC
progression.
We also directly examined the extracellular matrix pro-
tein laminin isoform, laminin alpha5 (LAMA5). Laminin
isoforms have been shown to play crucial roles in modu-
lating cell adhesion, proliferation, differentiation, and
migration in normal and pathological states by interact-
ing with other extracellular matrix components [39,40].
In both microarray and by quantitative RT-PCR we
found that LAMA5 mRNA expression was specifically
increased in CT- and PF-derived cells compared to DC-
derived fibroblasts (Figure 5b and 6b). A previous study
by Kosmehl et al., (1995) [41] showed higher expression
of laminin A, as well as M, B1, B2 and S chains, in
Dupuytren nodular tissues, but LAMA5 expression in
cord tissue is unknown. Further dissection of the func-
tional significance LAMA5 might provide valuable
insights for manipulation to limit the progression of DC.
In contrast to ANGPTL7 and LAMA5, direct examina-
tion of Shroom2 message showed a marked increase in
DC-derived cells (~ 5-6- fold) compared to CT- or PF-
derived fibroblasts, again mirroring the findings from the
microarray data (Figures 5c &6c). Shroom family proteins
are reported to interact with actin and actin polymeriza-
tion is required for their function [42,43]. Moreover,
members of the Shroom family (mainly Shrooms 1, 2 and
3) cause accumulation of g-tubulin, a microtubule nucle-
ating protein, at the apical surface of epithelial cells [44].
Based on these and other findings it has been suggested
that Shroom genes function in the regulated control of
cytoskeletal molecules and thereby aid in cell morpho-
genesis. We have found that interference with actin path-
ways can affect Dupuytren’s fibroblast contractility
(Satish et al., manuscript in preparation) and enhanced
levels of Shroom 2 may, be one of the factors that alter
actin-mediated cell contraction in DC, potentially identi-
fying it as an attractive target through which to inhibit
disease progression or recurrence.
Ingenuity analysis of our differentially expressed gene
sets has identified multiple microRNAs that may play a
role in DC pathophysiology, although direct experimen-
tal evidence is as yet lacking. Recently Mosakhani et al.,
[45] for the first time examined expression of micro-
RNAs in affected DC tissues, comparing them to normal
fibroblasts in culture and normal fascia obtained from
hand trauma and carpal tunnel patients. Curiously,
although they identified dozens of differentially
expressed microRNAs, none of the microRNAs sug-
gested by our Ingenuity analysis appeared in their
screen. This may be due to the disparate natures of the
sample sources (ie. tissues containing a mixture of cells
of mesenchymal, endothelial and other lineages versus
primary fibroblasts in culture) or other reasons, such as
the absence of mechanical stress to activate mechanore-
ceptors, or additional extra-cellular matrix components
and matricellular molecules that may, directly or indir-
ectly, regulate microRNA transcription. We anticipate
that additional analyses incorporating some or all of
these potential effectors of DC development in vivo will
be required to establish the full relevance of the differ-
ential gene expression patterns we report here.
Conclusions
These data show that the transcriptomic profiles of DC-
disease fibroblasts and fibroblasts from unaffected pal-
mar fascia in DC patients are highly similar, and differ
significantly from the transcriptomic profiles of fibro-
blasts from the palmar fascia of patients undergoing car-
pal tunnel release. These observations are further
evidence of an inherent molecular pathophysiology in
DC disease fibroblasts that may help to explain the pro-
gression of the disease and its tendency to recurrence.
Additional material
Additional file 1: Differences in individual gene expression levels
identified through SAM analysis.
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